|
Virus | Antiviral substances | Description of antiviral activity type | Reference |
|
HIV | Curcumin | Inhibition of HIV-1 LTR-directed gene expression | [24] |
Curcumin, reduced curcumin, allyl-curcumin, tocopheryl-curcumin | Inhibition of Tat-mediated transactivation of HIV-1 LTR | [25] |
Curcumin, curcumin boron complexes | Inhibition of HIV-1 and HIV-2 proteases | [26] |
Curcumin | Inhibition of HIV-1 Integrase | [27] |
Curcumin | Inhibition of Tat protein acetylation | [28] |
Curcumin | No antiviral effect in clinical trial | [29] |
Influenza | Curcumin | Inhibition of haemagglutination | [30] |
HSV-1 | Curcumin, gallium-curcumin, Cu-curcumin | Reduction of HSV-1 replication | [31, 32] |
HSV-2 | Curcumin | Significant protection in mouse model | [33] |
Coxsackievirus | Curcumin | Replication inhibition through UPS dysregulation | [34] |
HBV | Aqueous extract | Suppression of HBV replication by increasing the p53 level | [35] |
HCV | Curcumin | Decrease of HCV replication by suppressing the Akt-SREBP-1 pathway | [36] |
HPV | Curcumin | Inhibition expression of viral oncoproteins of E6 and E7 | [37] |
HPV | Curcumin | Downregulation effect on the transcription of HPV-18 | [38] |
JEV | Curcumin | Reduction in production of infective viral particles | [39] |
HTLV-1 | Curcumin | Downregulation of JunD protein in HTLV-1-infected T-cell lines | [40] |
|